Logistic models with five serum biomarkers for preoperative differentiation of benign ovarian tumors from ovarian carcinoma

Authors

  • V. Racheva Clinical Laboratory, University Multiprofile Hospital for Active Treatment "Sveta Marina" – Pleven; Medical University – Pleven Author

Keywords:

ovarian carcinoma, benign ovarian tumors, biomarkers, logistic model, CA125, apolipoprotein А1, prealbumin, transferrin, β2-microglobulin

Abstract

Ovarian carcinoma (OC) is one of the leading causes of mortality in women with oncological diseases of the reproductive system. The disease is often diagnosed at an advanced stage due to the lack of characteristic symptoms and effective screening strategies. Early differentiation of benign ovarian tumors (BOT) from OC is of key importance for choosing the optimal surgical tactics and improving the long-term prognosis. Classical diagnostic methods, including imaging studies and determination of tumor markers such as CA125, often do not provide sufficient sensitivity and specificity. Therefore, multivariate models are being developed that combine biomarkers and clinical parameters for a more accurate risk assessment. By determining the concentrations of five serum proteins – transthyretin, transferrin, apolipoprotein А1, β2 microglobulin and CA125 and monitoring their diagnostic abilities using logistic regression, we created formulas that can be implemented in a computer program. Their application after a gynecological examination and the detection of an ovarian tumor would be useful in preoperative differential diagnosis.

References

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Karpinskyj C, et al. Improved early detection of ovarian cancer using longitudinal multimarker models. PLoS Med. 2020;17(4):e1003350.

Zhang Z, Bast RC Jr, Yu Y, Li J, Zou T, Connolly DC, et al. Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. Clin Chem. 2020;66(12):1599-1608.

Alvarado-Castillo D, Pardo C, Peña MT, et al. Nomogram development for predicting ovarian tumor malignancy using inflammatory biomarker and CA-125. J Ovarian Res. 2024;17(1):101.

Kaijser J, Anttila M, Huvila J, et al. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status. Gynecol Oncol. 2012;124(2):310-6.

Bast RC Jr, Hennessy B, Mills GB. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019;12:28.

Andersen M, Beale P, Howells RE, et al. Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. J Transl Med. 2012;10:45.

Van Gorp T, Cadron I, Despierre E, et al. Biomarker-based models for preoperative assessment of adnexal mass: a multicenter validation study. J Clin Oncol. 2022;40(11):e111-e124.

Zheng M, Bian H, Shu L, et al. Exosomal biomarkers in the differential diagnosis of ovarian tumors: the emerging roles of CA125, HE4, and C5a. J Ovarian Res. 2023;16(1):123.

Т. Семова, Д. Димитров, Н. Хинкова, М. Василева, Е. Петкова Първични синхронни тумори на ендометриума и яйчника – едноцентрово ретроспективно проучване. Български медицински журнал, 2024, 18(4), 42-50.

Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008;452(7187):571-9.

Su F, Lang J, Kumar A, et al. Identification of human serum biomarkers for detection of ovarian cancer using high-density antibody microarrays. Cancer Epidemiol Biomarkers Prev. 2012;21(11):1902-12.

Zhang Z, Yu Y, Xu F, et al. Combining ApoA1, transthyretin and transferrin as serum biomarkers for preoperative discrimination of benign and malignant ovarian tumors. Clin Cancer Res. 2019;25(16):5105-12.

Published

28.04.2026

How to Cite

Logistic models with five serum biomarkers for preoperative differentiation of benign ovarian tumors from ovarian carcinoma (V. Racheva , Trans.). (2026). Bulgarian Medical Journal, 20(1), 39-42. https://journals.mu-sofia.bg/index.php/bmj/article/view/798